These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21470099)

  • 41. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in design of potential quinoxaline anti-infectives.
    Jampilek J
    Curr Med Chem; 2014; 21(38):4347-73. PubMed ID: 25312209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2D QSAR Analysis of Substituted Quinoxalines for their Antitubercular and Antileptospiral Activities.
    Natarajan R; Puratchikody A; Muralidharan V; Doble M; Subramani A
    Curr Comput Aided Drug Des; 2019; 15(2):182-192. PubMed ID: 30317999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro antimicrobial activities of animal-used quinoxaline 1,4-di-N-oxides against mycobacteria, mycoplasma and fungi.
    Zhao Y; Cheng G; Hao H; Pan Y; Liu Z; Dai M; Yuan Z
    BMC Vet Res; 2016 Sep; 12(1):186. PubMed ID: 27600955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BM 212 and its derivatives as a new class of antimycobacterial active agents.
    Biava M
    Curr Med Chem; 2002 Nov; 9(21):1859-69. PubMed ID: 12369872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.
    Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC
    Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel antimalarial chloroquine- and primaquine-quinoxaline 1,4-di-N-oxide hybrids: Design, synthesis, Plasmodium life cycle stage profile, and preliminary toxicity studies.
    Bonilla-Ramirez L; Rios A; Quiliano M; Ramirez-Calderon G; Beltrán-Hortelano I; Franetich JF; Corcuera L; Bordessoulles M; Vettorazzi A; López de Cerain A; Aldana I; Mazier D; Pabón A; Galiano S
    Eur J Med Chem; 2018 Oct; 158():68-81. PubMed ID: 30199706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
    Xu Z; Gao C; Ren QC; Song XF; Feng LS; Lv ZS
    Eur J Med Chem; 2017 Oct; 139():429-440. PubMed ID: 28818767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring 3-arylquinoxaline-2-carbonitrile 1,4-di-N-oxides activities against neglected diseases with QSAR.
    Vicente E; Duchowicz PR; Ortiz Edel V; Monge A; Castro EA
    Chem Biol Drug Des; 2010 Jul; 76(1):59-69. PubMed ID: 20492446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di-
    González-González A; Sánchez-Sánchez O; Wan B; Franzblau S; Palos I; Espinoza-Hicks JC; Moreno-Rodríguez A; Martínez-Vázquez AV; Lara-Ramírez EE; Ortiz-Pérez E; Paz-González AD; Rivera G
    RSC Med Chem; 2024 Aug; 15(8):2785-2791. PubMed ID: 39149106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nontoxic Metal-Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis.
    Yu M; Nagalingam G; Ellis S; Martinez E; Sintchenko V; Spain M; Rutledge PJ; Todd MH; Triccas JA
    J Med Chem; 2016 Jun; 59(12):5917-21. PubMed ID: 27214150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quinoxaline derivatives as potential antituberculotic agents.
    Kunes J; Spulák M; Waisser K; Slosárek M; Janota J
    Pharmazie; 2000 Nov; 55(11):858-9. PubMed ID: 11126007
    [No Abstract]   [Full Text] [Related]  

  • 54. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
    Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
    Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
    Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP
    J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles.
    Montoya ME; Sainz Y; Ortega MA; Lopez De Cerain A; Monge A
    Farmaco; 1998; 53(8-9):570-3. PubMed ID: 10081819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
    Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
    Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. QSAR analysis for quinoxaline-2-carboxylate 1,4-di-N-oxides as anti-mycobacterial agents.
    Vicente E; Duchowicz PR; Castro EA; Monge A
    J Mol Graph Model; 2009 Aug; 28(1):28-36. PubMed ID: 19394254
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemistry, biological properties and SAR analysis of quinoxalinones.
    Carta A; Piras S; Loriga G; Paglietti G
    Mini Rev Med Chem; 2006 Nov; 6(11):1179-200. PubMed ID: 17100630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.
    Pieroni M; Lilienkampf A; Wan B; Wang Y; Franzblau SG; Kozikowski AP
    J Med Chem; 2009 Oct; 52(20):6287-96. PubMed ID: 19757815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.